

THE LEONA M. AND HARRY B.

HELMSLEY


CHARITABLE TRUST

Understanding and Preventing Hypoglycemia in Diabetes

One-day industry session on the occasion of the 60th Annual Meeting of the European Association for the Study of Diabetes.

9 September 2024

IFEMA Convention Center – Feria de Madrid, Warsaw Hall,
Avda. del Partenón, 5, 28042 Madrid, Spain



Agenda

9:00–9:15 AM	Welcome / Introduction Ben Williams, PhD, Helmsley Charitable Trust, United States Alvin C. Powers, MD, Vanderbilt University, United States
9:15–10:45 AM	Genetic and gene expression studies that aim to understand the cause of glucagon secretion defects in diabetes Session Chair: Gina Yosten, PhD, St. Louis University School of Medicine, United States
9:15–9:45 AM	Lori SusseL, PhD, University of Colorado Anschutz Medical Campus, United States Alphabet(a) soup: Unraveling cell fate decisions in the islet
9:45–9:55 AM	Q&A
10:00–10:30 AM	Joan Camuñas-Soler, PhD, University of Gothenburg, Sweden Cell dysfunction in diabetes: Insights from single-cell studies
10:30–10:40 AM	Q&A
10:45–11:00 AM	Break: Snacks and coffee
11:00 AM–12:00 PM	Short talks from submitted abstracts Session Chair: Jason Winnick, PhD, University of Cincinnati, United States
11:00–11:15 AM	Malin Fex, PhD, Lund University, Sweden Loss of the melatonin receptor type 1 (Mt1) results in dysregulated alpha cell function and metabolism
11:15–11:20 AM	Q&A
11:20–11:35 AM	Sebastian Barg, PhD, Uppsala University, Sweden Resistance to para- and autocrine inhibition causes hypersecretion of somatostatin in single delta cells of human diabetic donors
11:35–11:40 AM	Q&A
11:40–11:55 AM	Rui Gao, MBBS, PhD, University of Oxford, England Disruption of electrical coupling between beta and delta cells results in impaired glucagon response to hypoglycemia in type 1 diabetes
11:55–12:00 PM	Q&A
12:00–1:00 PM	Lunch

1:00–2:30 PM	Understanding and restoring alpha cell function in type 1 diabetes and type 2 diabetes: Intrinsic, paracrine, and <i>in vivo</i> consequences in humans. Session Chair: Shareen Forbes, MBChB, PhD, FRCP, University of Edinburgh, Scotland
1:00–1:15 PM	Dale Morrison, PhD, University of Melbourne, Australia Glucoregulatory impact of whey protein ingestion in adults with type 1 diabetes
1:15–1:20 PM	Q&A
1:20–1:35 PM	Quan Zhang, PhD, University of Oxford, England and University of Coimbra, Portugal Hypoglycemia sensitises negative feedback control of glucagon secretion underlies defective glucagon response in recurrent hypoglycemia
1:35–1:40 PM	Q&A
1:45–2:15 PM	Michael Rickels, MD, MS, University of Pennsylvania School of Medicine, United States Understanding and restoring alpha cell function in type 1 diabetes
2:15–2:25 PM	Q&A
2:30–2:45 PM	Break: Snacks and coffee
2:45–4:30 PM	Clinical progress and regulatory perspectives regarding pharmacological strategies to prevent hypoglycemia Session Chair: Marjana Marinac, PharmD, Breakthrough T1D, United States
2:50–3:00 PM	Marjana Marinac, PharmD, Breakthrough T1D, United States Outcomes beyond A1c and the patient perspective
3:00–3:10 PM	Karen Hauda, JD, MS, Novo Nordisk, United States Impact of health authority regulations on clinical development
3:10–3:20 PM	Asger Lund, MD, PhD, Copenhagen University Hospital Gentofte, Denmark Clinical trial designs to identify hypoglycemic prevention candidates — considerations and challenges
3:20–3:30 PM	Richard Liggins, PhD, Zucara Therapeutics, Canada ZT-01, a Somatostatin receptor 2 antagonist targets the alpha cell to restore glucagon counterregulation and prevent hypoglycemia: a phase 1 and 2 clinical update
3:30–4:30 PM	Discussion Session Karen Hauda, JD, MS, Novo Nordisk, United States Richard Liggins, PhD, Zucara Therapeutics, Canada Asger Lund, MD, PhD, Copenhagen University Hospital Gentofte, Denmark
4:30 PM	Closing Remarks Conchi Izquierdo, PhD, Helmsley Charitable Trust, United States Ben Williams, PhD, Helmsley Charitable Trust, United States
5:00–6:00 PM	Poster Session

THE LEONA M. AND HARRY B.
HELMSLEY
CHARITABLE TRUST

About Helmsley

The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting exceptional efforts in the U.S. and around the world in health and select place-based initiatives. Since beginning active grantmaking in 2008, Helmsley has committed more than \$4.5 billion for a wide range of charitable purposes. The Helmsley Type 1 Diabetes (T1D) Program is the largest private foundation funder in the world with a focus on T1D, with more than \$1 billion to date committed to transform the trajectory of the disease and to accelerate access to 21st century care, everywhere. For more information on Helmsley and its programs, visit helmsleytrust.org.

Connect with us!

in [linkedin.com/company/the-helmsley-charitable-trust](https://www.linkedin.com/company/the-helmsley-charitable-trust)

@ [@helmsleytrust](https://www.instagram.com/helmsleytrust)

@ [@helmsleytrust](https://www.tiktok.com/@helmsleytrust)

f [facebook.com/helmsleytrust](https://www.facebook.com/helmsleytrust)

X [@HelmsleyTrust](https://twitter.com/HelmsleyTrust)

Learn more about the Helmsley T1D Program:
helmsleytrust.org/type-1-diabetes

